NewLink re-evaluating Phase III plans for indoximod combo

By Jennie Walters | Apr 16, 2018 | 9:26 PM GMT

NewLink Genetics Corp. (NASDAQ:NLNK) said Sunday that it will not start the randomized, placebo-controlled portion of the Phase III Indigo301 trial to evaluate indoximod (NLG8189) plus anti-PD-1 mAbs Keytruda pembrolizumab or

Read the full 315 word article

How to gain access

Continue reading with a
two-week free trial.